UnitedHealth Group is under intense pressure from multiple government entities. This includes an antitrust probe and a separate criminal fraud investigation by the Department of Justice, alongside a proposed near-flat Medicare Advantage payment increase from the Trump administration, far below analyst expectations.
Beyond one-off events like the cyberattack, UNH's core financial health is weakening. The company's medical care ratio has increased significantly from 85.5% to 88.9%, indicating severe margin compression, and it projects a 2% revenue decline for 2026.
A key driver of UNH's poor performance is the sharp increase in its adjusted medical care ratio (MCR) to 88.9%. This metric, representing medical costs as a percentage of premiums, shows the company is spending significantly more to cover patient care, leaving less for administrative costs and profit.
The market's valuation of UNH has become deeply pessimistic, with a reverse DCF analysis showing only 4.9% annual free cash flow growth priced in. This contrasts sharply with Wall Street analysts who still project 16% annual EPS growth through 2029, creating a wide gap between current sentiment and future expectations.
Keep pulling the thread on UnitedHealth Group.